Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Brunner

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|March 21, 2015
Towards tailored radiopeptide therapyPiotr Radojewski, Rebecca Dumont, Nicolas Marincek, et al.
Hormone Molecular Biology and Clinical Investigation|December 19, 2017
Interest of systematic tomosynthesis (3D mammography) with synthetic 2D mammography in breast cancer screeningMathieu Liberatore, Jean-Michel Cucchi, Martine Fighiera, et al.
Clinical Imaging|November 9, 2005
Burst fracture of the spine involving vertebrae presenting no other lesions: the role of vertebroplastyNicolas Amoretti, Etienne Hovorka, Pierre-Yves Marcy, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 17, 2015
Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trialNicolas Marincek, Piotr Radojewski, Rebecca A Dumont, et al.
Cardiovascular and Interventional Radiology|June 26, 2009
Computed axial tomography-guided fixation of sacroiliac joint disruption: safety, outcomes, and results at 3-year follow-upNicolas Amoretti, Istvan Hovorka, Pierre-Yves Marcy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2011
Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancersAnna Imhof, Philippe Brunner, Nicolas Marincek, et al.
American Journal of Nuclear Medicine and Molecular Imaging|January 28, 2015
Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinomaRebecca A Dumont, Daniela Seiler, Nicolas Marincek, et al.
Journal of Translational Medicine|January 17, 2013
Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation studyNicolas Marincek, Ann-Catherine Jörg, Philippe Brunner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 17, 2016
Diabetes Mellitus and Its Effects on All-Cause Mortality After Radiopeptide Therapy for Neuroendocrine TumorsMaria Umlauft, Piotr Radojewski, Petar-Marko Spanjol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2012
Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancersLinda Villard, Anna Romer, Nicolas Marincek, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
European Journal of Nuclear Medicine and Molecular Imaging|March 21, 2015
Towards tailored radiopeptide therapyPiotr Radojewski, Rebecca Dumont, Nicolas Marincek, et al.
Hormone Molecular Biology and Clinical Investigation|December 19, 2017
Interest of systematic tomosynthesis (3D mammography) with synthetic 2D mammography in breast cancer screeningMathieu Liberatore, Jean-Michel Cucchi, Martine Fighiera, et al.
Clinical Imaging|November 9, 2005
Burst fracture of the spine involving vertebrae presenting no other lesions: the role of vertebroplastyNicolas Amoretti, Etienne Hovorka, Pierre-Yves Marcy, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 17, 2015
Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trialNicolas Marincek, Piotr Radojewski, Rebecca A Dumont, et al.
Cardiovascular and Interventional Radiology|June 26, 2009
Computed axial tomography-guided fixation of sacroiliac joint disruption: safety, outcomes, and results at 3-year follow-upNicolas Amoretti, Istvan Hovorka, Pierre-Yves Marcy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2011
Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancersAnna Imhof, Philippe Brunner, Nicolas Marincek, et al.
American Journal of Nuclear Medicine and Molecular Imaging|January 28, 2015
Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinomaRebecca A Dumont, Daniela Seiler, Nicolas Marincek, et al.
Journal of Translational Medicine|January 17, 2013
Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation studyNicolas Marincek, Ann-Catherine Jörg, Philippe Brunner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 17, 2016
Diabetes Mellitus and Its Effects on All-Cause Mortality After Radiopeptide Therapy for Neuroendocrine TumorsMaria Umlauft, Piotr Radojewski, Petar-Marko Spanjol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2012
Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancersLinda Villard, Anna Romer, Nicolas Marincek, et al.
Pageof 4